Pasithea Therapeutics KTTA
NASDAQ KTTA
$0.54 +0.07 (+14.77%)
At close: Aug 21, 2026 · 4:00 PM EDT

Pasithea Therapeutics (KTTA) Net Equity Issued and Repurchased (2024 - 2025)

Pasithea Therapeutics (KTTA) posted Net Equity Issued and Repurchased of -$2.1 million for Q4 2025, down 196.93% sequentially from $2.2 million in Q3 2025.

Pasithea Therapeutics (KTTA) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends

Pasithea Therapeutics has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at -$2.1 million in Q4 2025.

  • Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.1 million (changed N/A YoY) and the FY2025 annual result came in at $2.1 million, down 53.99% from the prior year.
  • Net Equity Issued and Repurchased retreated to -$2.1 million in Q4 2025 per KTTA's latest filing, from $2.2 million in the prior quarter.
  • Over five years, Net Equity Issued and Repurchased peaked at $4.5 million in Q3 2024 and troughed at -$2.1 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Pasithea Therapeutics 16.97 Mn 16.97 Mn - 358,037.00

Historic Data

Download Data
DateValue
Dec 31, 2025 -2.14 Mn
Dec 31, 2025 -2.14 Mn
Sep 30, 2025 2.20 Mn
Sep 30, 2025 2.20 Mn
Jun 30, 2025 358,037.00
Jun 30, 2025 358,037.00
Mar 31, 2025 1.65 Mn
Mar 31, 2025 1.65 Mn
Sep 30, 2024 4.50 Mn
Sep 30, 2024 4.50 Mn